Immunate

Human Coagulation Factor VIII and Human Von Willebrand Factor, the active ingredient in Immunate, is a coagulation factor replacement presented as a sterile concentrate for intravenous use. It supplies deficient clotting factors to restore hemostasis in patients with hemophilia A and von Willebrand disease.

GNH USA supplies Immunate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, meeting stringent quality standards and regulatory requirements. The product is manufactured under GMP conditions and distributed with cold‑chain logistics to preserve stability.

Immunate is used to replace deficient clotting factors in the coagulation cascade for inherited bleeding disorders.

- Hemophilia A: Provides factor VIII to achieve adequate clot formation and reduce bleeding episodes. - Von Willebrand disease: Supplies von Willebrand factor to improve platelet adhesion and stabilize factor VIII, decreasing bleeding frequency. - Surgical or invasive procedures: Offers temporary hemostatic coverage to prevent peri‑operative bleeding in patients with hemophilia A or von Willebrand disease.

Common Side Effects: - Infusion‑related reactions such as chills or flushing. - Fever or mild temperature elevation. - Headache. - Nausea or vomiting.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of neutralizing antibodies (inhibitors) against factor VIII or VWF. - Thromboembolic events, including deep vein thrombosis or pulmonary embolism.

Before initiating therapy, assess inhibitor status and baseline clotting parameters.

- Monitor for signs of allergic reaction during infusion: stop infusion if severe symptoms occur. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Avoid concurrent use with other pro‑coagulant agents unless clinically indicated. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Immunate may interact with other agents affecting hemostasis.

Major Interactions (Avoid): - Concurrent use with activated prothrombin complex concentrates (aPCC) may increase thrombosis risk. - Combined therapy with other clotting factor concentrates can lead to excess clot formation. - Use with high‑dose anticoagulants (e.g., warfarin, heparin) may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Desmopressin (DDAVP) may augment VWF levels; monitor for hypercoagulability. - NSAIDs can increase bleeding tendency; observe for signs of hemorrhage. - Immunosuppressants may affect inhibitor development; assess inhibitor titres regularly.